RIBOFLAVIN ( DrugBank: Riboflavin )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
38	スティーヴンス・ジョンソン症候群	1
46	悪性関節リウマチ	1
96	クローン病	2
97	潰瘍性大腸炎	2
162	類天疱瘡（後天性表皮水疱症を含む。）	1
168	エーラス・ダンロス症候群	1
265	脂肪萎縮症	1

38. スティーヴンス・ジョンソン症候群

臨床試験数 : 17 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01582880 (ClinicalTrials.gov)	March 2012	10/4/2012	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases	Drug: Riboflavin	Joseph B. Ciolino, MD	NULL	Completed	18 Years	N/A	All	1	Phase 1/Phase 2	United States

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01582880 (ClinicalTrials.gov)	March 2012	10/4/2012	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases	Drug: Riboflavin	Joseph B. Ciolino, MD	NULL	Completed	18 Years	N/A	All	1	Phase 1/Phase 2	United States

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02769494 (ClinicalTrials.gov)	March 2016	9/3/2016	The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer	The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease	Crohn's Disease;Oral Ulcer	Drug: Mesalazine Sustained-Release Tablets;Drug: Riboflavin Sodium Phosphate Injection	Xijing Hospital of Digestive Diseases	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 3	China
2	NCT02538354 (ClinicalTrials.gov)	March 2016	20/8/2015	The Effect of Riboflavin in Crohn's Disease	The Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's Disease	Crohn Disease	Dietary Supplement: Riboflavin supplementation	University Medical Center Groningen	NULL	Completed	18 Years	65 Years	All	70	N/A	Netherlands

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-002542-38-DK (EUCTR)	28/11/2007	08/11/2007	A clinical study to explore the safe and effective use of the drug sotrastaurin in patients with ulcerative colitis	A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis. - A2210	Ulcerative colitis MedDRA version: 14.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Sotrastaurin Product Code: AEB071 INN or Proposed INN: Sotrastaurin (INN) acetate Product Name: Vitamin B2 INN or Proposed INN: Riboflavin	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	Denmark;Germany
2	EUCTR2007-002542-38-DE (EUCTR)	29/10/2007	22/02/2008	A clinical study to explore the safe and effective use of the drugsotrastaurin in patients with ulcerative colitis	A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis.	Ulcerative colitis MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: AEB071A Trade Name: B2-ASmedic Product Name: B2-ASmedic INN or Proposed INN: RIBOFLAVIN	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	60		Denmark;Germany

162. 類天疱瘡（後天性表皮水疱症を含む。）

臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01582880 (ClinicalTrials.gov)	March 2012	10/4/2012	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases	Drug: Riboflavin	Joseph B. Ciolino, MD	NULL	Completed	18 Years	N/A	All	1	Phase 1/Phase 2	United States

168. エーラス・ダンロス症候群

臨床試験数 : 13 / 薬物数 : 21 - (DrugBank : 11) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01307527 (ClinicalTrials.gov)	November 2008	1/3/2011	Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI		Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6	Drug: Riboflavin;Device: Kera-X	Hadassah Medical Organization	NULL	Enrolling by invitation	18 Years	N/A	Both	1	N/A	Israel

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00202228 (ClinicalTrials.gov)	July 2002	13/9/2005	Lactate Metabolism Study in HIV Infected Persons	Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.	HIV Infections;AIDS;Lactic Acidosis;Lipodystrophy	Drug: cofactor supplementation (thiamine, riboflavin, L-carnitine)	Queen's University	Ontario HIV Treatment Network	Completed	18 Years	N/A	Both	30	Phase 4	Canada

先頭へ